^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) + Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
122MO - Cemiplimab (cemi) + Platinum Doublet Chemotherapy (chemo) + Ipilimumab (ipi) for First-Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC): EMPOWER-Lung 3 Part 1
Published date:
12/01/2022
Excerpt:
In EMPOWER-Lung 3 part 1, 323 pts with PD-L1 expression of <50% were randomized (1:1:1) to: standard platinum-based doublet chemo for 4 cycles (StC), cemi 350 mg once every 3 weeks (Q3W)….Med PFS was 6.4m vs 6.3m with HR of 0.813 (0.596, 1.108). ORR was 35.8% and 28.3% for CIC and StC, respectively. Med duration of response was 15.9m vs 6.3m. Safety profile was generally consistent with the known safety profile for cemi, chemo, and ipi....In this descriptive analysis, the addition of cemi and ipi to a reduced course of chemo led to a meaningful OS benefit in pts with PD-L1 <50%.
Secondary therapy:
Chemotherapy
Trial ID:
